drug

fostamatinib

1 story · latest Aug 4, 2026

Status: FDA approved Apr 2018 · NDA209299
Brand: Tavalisse

Relationships

Developed by Rigel Pharmaceuticals Inc

Timeline

Rigel adds VEPPANU to portfolio, keeps R289 timeline, raises 2026 revenue guidance

Aug 4Quarterly updateRigel Pharmaceuticals Inc vepdegestrant

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.